Back to the full story3 sources · FDA clears Roche and Eli Lilly's Alzheimer's blood test for primary and specialty care◆ Analytics
FDA clears Roche and Eli Lilly's Alzheimer's blood test for primary and specialty care
Deterministic text analytics computed across all 3 sources. Frequency, entity overlap, and claim overlap — computed counts only. Nothing is rated true or false.
01
Frequency Analytics
The most common words and exact phrases across every report in this cluster. Computed counts only.
Top words
testalzheimerrochelillybloodelecsysptau217specialtypathologycognitive
Top phrases
alzheimer blood testalzheimer bloodblood testeli lillyeli lilly alzheimer blood testlilly alzheimer blood testeli lilly alzheimer bloodlilly alzheimer bloodelecsys ptau217 testeli lilly alzheimer
02
Entity Overlap
Names detected in the report text: which appear across multiple sources, and which only one source mentions.
Across multiple sources
- Roche · 2 sources
Unique to one source
- Eli Lilly's Alzheimer's · Quartz
- The Elecsys · Quartz
- Eli Lilly’s Alzheimer’s · The Straits Times
- US FDA · The Straits Times
- European · The Straits Times
03
Claim Overlap
Near-identical sentences found in two or more reports, versus sentences that appear in only one. Text match only — nothing is rated true or false.
Repeated across sources
No sentence appeared in more than one source.
Appears once
- "The Elecsys pTau217 test can help doctors assess amyloid pathology in people 55 and older showing signs of cognitive decline The Elecsys pTau217 test can help doctors assess amyloid pathology in people 55 and older showing signs of cognitive decline" · Quartz
- "The nod follows European approval for the Elecsys pTau217 test in May." · The Straits Times